| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
The primary targets of 11-Oxomogroside IIIE are not well-defined as a specific receptor or enzyme, as it is a natural product glycoside rather than a targeted pharmaceutical agent. The compound belongs to the mogroside family of cucurbitane triterpene glycosides, which are known for their sweet taste and potential therapeutic properties. These compounds may interact with various biological targets, including sweet taste receptors and metabolic pathways. 11-Oxomogroside IIIE has been identified as an EBV-EA inhibitor, suggesting potential antiviral or immunomodulatory activities. Further research is needed to fully characterize its molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
In vitro studies of 11-Oxomogroside IIIE are limited, as it is primarily a natural product and analytical reference standard rather than a drug candidate. The compound has been shown to inhibit EBV-EA (Epstein-Barr virus early antigen) activation, suggesting potential antiviral activity. As a cucurbitane triterpene glycoside, it may also exhibit other biological activities, including anti-inflammatory, antioxidant, or metabolic effects. The compound's intense sweetness, which is 300 times sweeter than sugar, makes it of interest for studies on sweet taste receptors and natural sweeteners. Further in vitro studies are needed to characterize its full biological activity profile.
|
| ln Vivo |
In vivo studies of 11-Oxomogroside IIIE are limited, as it is primarily a natural product isolated from monk fruit rather than a therapeutic agent. Monk fruit extracts containing mogrosides have been consumed as natural sweeteners and traditional medicines for centuries. The compound may have potential health benefits related to its antioxidant, anti-inflammatory, or metabolic effects. Further in vivo studies are needed to evaluate its pharmacokinetic properties, bioavailability, and therapeutic potential in animal models of various diseases. The compound's traditional use as a pulmonary demulcent suggests potential applications in respiratory conditions.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, 11-Oxomogroside IIIE can be evaluated using various biochemical assays to characterize its biological activities. As an EBV-EA inhibitor, the compound can be tested in assays measuring Epstein-Barr virus early antigen activation. Binding to sweet taste receptors can be assessed using cell-based receptor assays. The compound's antioxidant activity can be evaluated using DPPH, ABTS, or other free radical scavenging assays. Standard assay conditions include appropriate buffer systems and controls. Dose-response curves are generated to determine IC₅0 values for various activities.
|
| Cell Assay |
For in vitro cellular experiments, 11-Oxomogroside IIIE can be tested in various cell lines to evaluate its biological activities. Cells are cultured in appropriate media and treated with various concentrations of the compound. Antiviral activity can be assessed in EBV-infected cells by measuring viral antigen expression. Antioxidant effects can be evaluated by measuring cellular reactive oxygen species (ROS) levels. Anti-inflammatory activity can be assessed by measuring cytokine production or NF-kappaB activation. Cell viability and cytotoxicity are monitored using standard assays such as MTT. The compound's effects on cellular metabolism and signaling pathways can be further investigated.
|
| Animal Protocol |
For in vivo animal experiments, 11-Oxomogroside IIIE can be administered to rodents via various routes including oral gavage, intravenous injection, or intraperitoneal injection. The compound's traditional use as a pulmonary demulcent suggests it could be studied in animal models of respiratory conditions, such as cough or inflammation. Metabolic effects could be evaluated in models of diabetes or obesity. Typical doses may range from 1 to 100 mg/kg depending on the study objectives. Physiological parameters such as blood glucose, inflammatory markers, and organ function are measured. Animal studies should follow appropriate ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 11-Oxomogroside IIIE are not extensively characterized in the literature. As a glycoside with a molecular weight of 961.2 g/mol, it would be expected to have low oral bioavailability due to poor absorption and potential degradation in the gastrointestinal tract. When administered systemically, the compound would likely be metabolized by gut microbiota and liver enzymes. Its half-life in circulation would depend on its stability and clearance mechanisms. Further pharmacokinetic studies would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile in vivo.
|
| Toxicity/Toxicokinetics |
Toxicological data for 11-Oxomogroside IIIE are limited, as it is primarily a natural product. Monk fruit extracts containing mogrosides have been consumed as natural sweeteners for centuries and are generally recognized as safe. The compound is considered to have low toxicity at concentrations typically used for research. Standard toxicological assessments would include cytotoxicity screening in relevant cell lines and preliminary in vivo toxicity in rodent models. As with all research chemicals, appropriate safety precautions should be taken when handling 11-Oxomogroside IIIE, including the use of personal protective equipment and adherence to institutional safety guidelines.
|
| References | |
| Additional Infomation |
11-Oxomogroside IIIE is a research compound isolated from monk fruit (Siraitia grosvenorii). No clinical trials or regulatory approvals have been reported for this specific compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a cucurbitane triterpene glycoside with intense sweetness (300 times sweeter than sugar) and has been used in traditional Chinese medicine as a pulmonary demulcent. It is also identified as an EBV-EA inhibitor.
|
| Molecular Formula |
C48H80O19
|
|---|---|
| Molecular Weight |
961.137417793274
|
| Exact Mass |
960.529
|
| CAS # |
2096516-68-4
|
| PubChem CID |
132606976
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
67
|
| Complexity |
1760
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
O=C1C[C@]2(C)[C@@H]([C@H](C)CC[C@H](C(C)(C)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)CC[C@@]2(C)[C@@H]2CC=C3C(C)(C)[C@H](CC[C@H]3[C@@]21C)O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O
|
| InChi Key |
QVTPQPDYCBHPCC-WTFJSKLNSA-N
|
| InChi Code |
InChI=1S/C48H80O19/c1-21(9-13-31(45(4,5)61)66-43-40(37(58)34(55)27(20-51)64-43)67-42-39(60)36(57)33(54)26(19-50)63-42)22-15-16-46(6)28-12-10-23-24(48(28,8)29(52)17-47(22,46)7)11-14-30(44(23,2)3)65-41-38(59)35(56)32(53)25(18-49)62-41/h10,21-22,24-28,30-43,49-51,53-61H,9,11-20H2,1-8H3/t21-,22-,24-,25-,26-,27-,28+,30+,31-,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,46+,47-,48+/m1/s1
|
| Chemical Name |
(3S,8S,9R,10R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~104.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0404 mL | 5.2022 mL | 10.4043 mL | |
| 5 mM | 0.2081 mL | 1.0404 mL | 2.0809 mL | |
| 10 mM | 0.1040 mL | 0.5202 mL | 1.0404 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
